Form 4: Bionano Genomics Officer Reports Tax Withholding Transaction

Principal Accounting Officer Mark Adamchak reported the withholding of 7 shares of common stock to satisfy tax obligations related to an RSU award.

Summary

• Mark Adamchak, Principal Accounting Officer of Bionano Genomics, Inc., engaged in a transaction involving the withholding of 7 shares of common stock.
• The transaction occurred on June 3, 2026, at a price of $1.30 per share.
• The withholding was executed to satisfy tax obligations associated with the vesting of a Restricted Stock Unit (RSU) award granted on June 3, 2024.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative tax withholding transaction by an insider.

Positives

• The transaction is a routine administrative action related to tax withholding upon the vesting of equity compensation, rather than a discretionary sale of shares.

Negatives

• The transaction reflects a minor reduction in the reporting person's direct beneficial ownership of company stock.

Risks

• None identified; this is a standard regulatory filing for tax compliance.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Industry Context

StockSavvy.ai notes that this filing is a standard regulatory disclosure for executive equity compensation and does not indicate a change in corporate strategy or financial performance.

Comparison to Industry Standards

• This transaction is consistent with standard corporate governance practices regarding the settlement of equity-based compensation for executives.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a routine tax-related equity settlement.

Key Dates

Keywords

Bionano Genomics, BNGO, Form 4, Insider Transaction, Tax Withholding, Equity Compensation